Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
The aim of this postmarketing surveillance is to obtain further information about the
 tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic
 obstructive respiratory tract disease under conditions of daily practice
Inclusion Criteria:

 -  Patients of either sex, including children over 6 years

 -  Chronic obstructive respiratory tract disease. Every doctor was asked to include in
 this study the first patients coming after each other, who were treated for the first
 time with Berodual® metered dose inhaler (MDI)

 Exclusion Criteria:

 -  Contraindications listed in the Instructions for Use/Summary of Product
 Characteristics of Berodual® metered-dose inhaler